Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
about
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumorsNew trends in molecular and cellular biomarker discovery for colorectal cancerMEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapyOncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer CellsMelanoma: oncogenic drivers and the immune systemCombination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done YetTargeting molecular addictions in cancerAdaptive resistance to targeted therapies in cancerBeyond BRAF: where next for melanoma therapy?Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondAdvances in targeting signal transduction pathwaysMolecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibitionLoss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.Metastatic colonization by circulating tumour cellsNegative feedback regulation of the ERK1/2 MAPK pathwayTargeting CDK4 and CDK6: From Discovery to TherapyThe PTEN Long N-tail is intrinsically disordered: increased viability for PTEN therapyFunction-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF InhibitorCombinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.An Integrative Platform of TCM Network Pharmacology and Its Application on a Herbal Formula, Qing-Luo-YinMAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.Miniaturized pre-clinical cancer models as research and diagnostic tools.Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal CancerCombined MEK and Pi3'-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo.Resistance to Raf inhibition in cancer.PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.Complexity of metastasis-associated SDF-1 ligand signaling in breast cancer stem cellsCytotoxic effects of 15-deoxy-Δ12,14-prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma in vitro.IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity.Evaluating melanoma drug response and therapeutic escape with quantitative proteomicsDevelopment, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancerCombined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.The MAPK pathway as an apoptosis enhancer in melanoma.A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.Change or die: targeting adaptive signaling to kinase inhibition in cancer cells.Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.
P2860
Q24294914-6F577283-34A0-40EF-A896-9B190589D8E7Q26739049-D1129F5C-7C1B-4A1C-8B4E-A6ACD17F266AQ26771192-6E6D8453-7F5B-4F5F-B9E9-A392230EA36CQ26774625-9E59ECBA-26B8-4B9C-A211-7E6D64B73ED1Q26775598-FBE11CFF-72FF-4E55-BA48-F18631BFD855Q26799864-9947BE15-2681-429C-99C2-8955E10C35D0Q26829525-FAC0C272-E4A3-4412-A98B-C04E49A25453Q26849316-539B7493-06B1-47C8-84A1-D0D2918AF710Q27006853-241C387F-17EF-4307-A98E-EB5F6975C988Q27026323-0185B4A2-A5CF-4E10-BBA6-72E0E1844EB5Q27686983-704DE3B8-475F-44FB-8A3C-3D4D5C9CC752Q27852128-F2B54ABF-2135-460D-9B41-BDB8128E858AQ27852692-9AD95A6D-938C-440C-95FD-03EA31A4C11BQ27852894-99433E09-779C-48C6-B8E1-E01A74C6D9B6Q27853121-57C55E40-A35C-49E2-BE56-21E734CE628DQ28076164-14DB8B36-FF72-4B43-A17D-1AB788B7599BQ28079202-EB8305AA-4681-4D9C-9449-886E866740B3Q28082912-DEAEDC9A-196F-4BD5-B22B-04BC400A2E6BQ28299026-3092597B-1349-4758-9037-8646127D6657Q29542169-0A2468EB-E6D6-47D8-9DA7-A222BFA5AFE6Q30277902-9EA2B9ED-DD86-462B-8E32-D3318185B902Q30393827-CCE62EE3-F74E-4617-9724-540381A794ECQ33566681-39F56A4E-3975-40B7-A137-1751DBB92706Q33605145-D91FE02C-E0D1-4E56-B522-732C7123F3C3Q33624491-E14DFEB1-E42A-405D-B35F-164244374433Q33648582-ECBD941B-67AB-41D9-9CD1-0E620739A288Q33651779-437C2D18-A1E5-45E1-B1C0-5C8EFE29893FQ33688428-6072E8DF-1315-48FA-8F69-8E4ABA24AAE6Q33694550-94DFF831-53A9-46BE-88CD-0EDBB96327EFQ33744855-8907C1FE-5380-48BE-9857-0CC57827A3B3Q33776852-D3305BBB-B1A6-4EA3-B520-8C1DA7BB7F23Q33850665-F6D06D78-FDA4-4758-8BB3-4C4AA73AB3B4Q33861173-E1EC275C-6522-4D9D-8BA0-D3C3B0303DEBQ33909942-FF3E92BE-EEAD-46CA-9585-CBA7A7540F57Q34100838-D1C51F93-5816-4446-8D42-703D8F6BFC1BQ34104135-9C5D95D7-D4FA-4B2E-B8DF-B932DCA1DA7EQ34132936-99BA490E-7015-45AD-B8F9-BA20590FFF47Q34225871-036E27C9-0FE4-4049-A278-748A175E695CQ34283481-C74519FD-1473-489A-B059-55F96F97A922Q34489987-1DFFDE46-10CF-4768-BAA7-E53F11FD8349
P2860
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Relief of profound feedback in ...... ctivity in BRAFV600E melanomas
@ast
Relief of profound feedback in ...... ctivity in BRAFV600E melanomas
@en
Relief of profound feedback in ...... ctivity in BRAFV600E melanomas
@en-gb
Relief of profound feedback in ...... ctivity in BRAFV600E melanomas
@nl
type
label
Relief of profound feedback in ...... ctivity in BRAFV600E melanomas
@ast
Relief of profound feedback in ...... ctivity in BRAFV600E melanomas
@en
Relief of profound feedback in ...... ctivity in BRAFV600E melanomas
@en-gb
Relief of profound feedback in ...... ctivity in BRAFV600E melanomas
@nl
prefLabel
Relief of profound feedback in ...... ctivity in BRAFV600E melanomas
@ast
Relief of profound feedback in ...... ctivity in BRAFV600E melanomas
@en
Relief of profound feedback in ...... ctivity in BRAFV600E melanomas
@en-gb
Relief of profound feedback in ...... ctivity in BRAFV600E melanomas
@nl
P2093
P2860
P3181
P1433
P1476
Relief of profound feedback in ...... ctivity in BRAFV600E melanomas
@en
P2093
Alan Huang
Christine A Pratilas
Ensar Halilovic
Eric W Joseph
James A Fagin
Jedd D Wolchok
Madhavi Tadi
Margaret K Callahan
Matthew Zubrowski
Neal Rosen
P2860
P304
P3181
P356
10.1016/J.CCR.2012.10.009
P407
P577
2012-11-13T00:00:00Z